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A B S T R A C T
Objective: Capturing trends in healthcare utilization may help to improve efficiencies in the detection and di-
agnosis of illness, to plan service delivery, and to forecast future health expenditures. For binge-eating disorder
(BED), issues include lengthy delays in detection and diagnosis, missed opportunities for recognition and
treatment, and morbidity. The study objective was to compare healthcare utilization and expenditure in people
with and without BED.
Methods: A case-control design and nationwide registers were used. All individuals diagnosed with BED at eating
disorder clinics in Sweden between 2005 and 2009 were included (N=319, 97% female, M age= 22 years).
Ten controls (N=3190) were matched to each case on age-, sex-, and location of birth. Inpatient, hospital-based
outpatient, and prescription medication utilization and expenditure were analyzed up to eight years before and
four years after the index date (i.e., date of diagnosis of the BED case).
Results: Cases had significantly higher inpatient, hospital-based outpatient, and prescription medication utili-
zation and expenditure compared with controls many years prior to and after diagnosis of BED. Utilization and
expenditure for controls was relatively stable over time, but for cases followed an inverted U-shape and peaked
at the index year. Care for somatic conditions normalized after the index year, but care for psychiatric conditions
remained significantly higher.
Conclusion: Individuals with BED had substantially higher healthcare utilization and costs in the years prior to
and after diagnosis of BED. Since previous research shows a delay in diagnosis, findings indicate clear oppor-
tunities for earlier detection and clinical management. Training of providers in detection, diagnosis, and man-
agement may help curtail morbidity. A reduction in healthcare utilization was observed after BED diagnosis.
This suggests that earlier diagnosis and treatment could improve long-term health outcomes and reduce the
economic burden associated with BED.
1. Introduction
Binge-eating disorder (BED) is characterized by the regular con-
sumption of unusually large amounts of food accompanied by a sense of
loss of control, in the absence of regular compensatory behaviors (e.g.,
self-induced vomiting) [1]. The lifetime prevalence is 3.5% in women
and 2.0% in men [2,3]. BED is associated with obesity, type 2 diabetes,
and suicide [2,4–7]. Despite its prevalence and somatic and psycholo-
gical comorbidities [2,4,7], few studies have considered health care
utilization and expenditure in individuals with BED [6,8–11].
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Investigating disease-specific healthcare utilization is crucial for fore-
casting demands on medical infrastructure and for guiding policy and
health service planning.
Grenon et al. [11] determined that average healthcare cost in the six
months prior to diagnosis was 36% higher for overweight women with
BED (n= 105) relative to the age-and-sex matched national norm.
Excluding non-overweight individuals may have biased the sample to-
ward greater utilization, and generalizability was limited by the lack of
an appropriate control group. Bellows et al. [8,9] compared electronic
health records of veterans with BED (n=257, 75% female) and
without BED. In the year following diagnosis, cases had higher inpatient
and psychotherapy use, longer inpatient stays, and more prescriptions
than controls. In the year preceding diagnosis, median total health care
expenditure did not differ significantly between the groups; however, in
the year following BED diagnosis, total cost doubled for cases. Greater
medication utilization in the year before and after diagnosis for people
with BED (n=238, 96% female) relative to matched controls was re-
ported in a nationwide Swedish register study [6].
Individuals with BED appear to have significantly greater healthcare
utilization, particularly in the year after detection, but evidence is
limited. Samples have been selective (i.e., overweight, veterans), and
observations were limited to the year before and after diagnosis. We fill
the gap in the healthcare utilization literature by studying a large,
population-based, longitudinal sample from Swedish nationwide reg-
ister data. Given the morbidity and typical delay in diagnosis and help-
seeking [12,13], we expected significantly greater and accelerating
utilization and expenditure among those with BED in the years pre-
ceding diagnosis, relative to controls. The analyses regarding the pat-
tern of utilization and expenditure after the index date are exploratory,
due to a lack of prior research.
2. Method
2.1. Study population
The sample (319 cases, 3190 controls, total N=3509) represents a
total population cohort (N=1,949,199) born between 1979 and 1993
identified in the Swedish registers. BED cases were identified from
Riksät and Stepwise—longitudinal quality assurance registers that cap-
ture nearly all individuals receiving inpatient, day patient, or outpatient
specialist eating disorder treatment in Sweden [14]. Criteria for inclu-
sion in Riksät and Stepwise are medical or self-referral to a participating
clinic, an eating disorder diagnosis by a medical provider, and intent-to-
treat the patient. For the Stepwise register, research participation is
elective via an opt out procedure (~3% decline participation [15]). All
patients with a DSM-IV [16] BED diagnosis between 2005 and 2009
were included as cases. In this study, the date of the first diagnosis of
BED represents the index date. The first diagnosis could occur at the
initial clinic presentation or at a follow-up evaluation after presentation
for another eating disorder. Follow-up eating disorder assessments
(available for ~69% of registrants) are annual while treatment is on-
going.
We ascertained 10 controls for each case using the Multi-Generation
Register [17] matched by sex, and year, month, and county of birth.
Controls were also matched on immigration status and time of migra-
tion (controls could not immigrate later than their respective cases) if
cases were born outside of Sweden. Controls had to be alive and a re-
sident in Sweden for an equivalent time period: from birth or im-
migration until the end of study follow-up of their index case. Controls
were not allowed to have received a BED diagnosis in Riksät or Stepwise,
but they could have had another eating disorder (which was detected in
0.7% of controls) recorded in Riksät, Stepwise, or the National Patient
Register [18].
The national personal identification number was used to link reg-
isters. The University of North Carolina Biomedical Institutional Review
Board and the Regional Ethics Committee of Karolinska Institutet
approved this study. Inclusion in Swedish population registers does not
require informed consent.
2.2. Measures
2.2.1. Demographics and comorbidity
Demographics were obtained from Sweden's Total Population
Register and Longitudinell Integrationsdatabas för Sjukförsäkrings- och
Arbetsmarknadsstudier (LISA: Longitudinal Integration Database for
Health Insurance and Labour Market Studies). Lifetime psychiatric co-
morbidity was obtained from the National Patient Register.
2.2.2. Healthcare utilization and expenditure
Inpatient admissions and hospital-based outpatient visits were
coded from the National Patient Register. For each participant, data were
obtained where available from 8 years prior to 4 years after the index
date (denoted year− 8 to year+ 4). The principal International
Classification of Diseases, Tenth Revision [19] (ICD-10) diagnostic code
for each occasion of service use was used to help establish costs. Cost
information was obtained from Sweden's Costs Per Patient database
which provides cost estimates annually based on individual patient
contact with hospital care according to the principal ICD diagnosis. ICD
comorbidities are recorded, but there is no adjustment to cost for these.
Using the principal ICD diagnosis for the healthcare occasion, inpatient
and outpatient utilization and expenditure were classified into psy-
chiatric and somatic.
Utilization and expenditure for medication prescriptions fills were
obtained from the Swedish Prescribed Drug Register, which contains
complete data (> 99%) for all medications prescribed and dispensed to
the entire Swedish population since July 1, 2005 [20].
Since this a newer database, only utilization four years before and
four years after the index date could be included (i.e., year −4 to year
4). The register uses the Anatomical Therapeutic Chemical (ATC)
classification system. Medication use was classified into psychiatric (N
codes) and somatic. See Supplementary Table S1 for information on
ATC codes and availability in the Swedish Prescribed Drug Register.
Costs equaled dispensed days× dose per day× corresponding unit
costs. Utilization and expenditure that occurred on the index date were
not included for all healthcare types. For further information on the
data, see Supplementary Table S2.
2.2.3. Currency and inflation
Expenditure was calculated in Swedish crowns (SEK) then inflated
to 2015 Swedish prices. Costs are reported in the tables and text in US
dollars (2015). The purchasing power parity based exchange rate in
2015 was 1.00 US dollar= 9.03 SEK [11].
2.2.4. Covariates
Factors that explain variability in healthcare utilization include low
socioeconomic status, advancing age, and female sex [21]. Parental
education and income were included as covariates, as proxies for so-
cioeconomic status. Parental education and income were obtained from
LISA for the index year. Parental education was assessed as the highest
level attained by either parent (primary school, secondary school, or
tertiary education). Income was assessed as the individual share of
disposable family income, and was obtained by calculating the sum of
family members' disposable income multiplied by individual con-
sumption weights (0.96 for adults), then divided by the total family
consumption weight. Net values in SEK were grouped into median splits
for analysis. Age and sex were accounted for already in the study de-
sign.
2.3. Statistical analysis
Hurdle models compared annual healthcare utilization and ex-
penditure between cases and controls. The hurdle likelihood function
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decomposes into two parts. The first part predicted the binary outcome
of utilization (or expenditure) and yielded an odds ratio (OR) from a
logistic distribution. The second part of the hurdle model, which is
conditional on having a strictly positive value for the first part (i.e., at
least one occasion of healthcare use), yielded an incident rate ratio
(IRR). For utilization outcomes, IRR is interpreted as the ratio of the
number of visits (or prescription fills), and for expenditure outcomes,
IRR is interpreted as the ratio of mean cost. The second part was fitted
with a negative binomial distribution and lognormal linear distribution,
for utilization and expenditure outcomes respectively. Because of the
low frequency of inpatient hospitalization, only the logistic regression
component is reported. Exact likelihood methods were used. The false
discovery rate (FDR) procedure corrected for multiple testing [22].
Bootstrap analyses accounted for uncertainty around the expected
values of utilization and expenditure. One thousand bootstrap re-
plicates were created for each parameter in the model, and during each
simulation one was drawn at random with replacement and used in the
calculation of the population mean and 95% confidence interval. For
utilization, the estimate represented the mean difference between cases
and controls. For expenditure, the ratio of expenditure (cases/controls)
was estimated. A positive confidence interval indicates that utilization/
expenditure is significantly higher among cases at the p < 0.05
threshold. A small portion of the bootstrap iterations failed to estimate
the distribution of the estimator because of low base rates of the out-
come and/or small cell sizes. Analyses were conducted with R 3.1.1.
3. Results
3.1. Sample descriptives
Three hundred and nineteen cases were identified. The average age
at the index date was 22.4 years (SD=3.4; range 14 to 29). Ninety-
seven percent (n= 308) were female and 91% (n= 290) were
Swedish-born. The average body mass index (BMI) at the time of di-
agnosis was 26.7 kg/m2 (SD=6.8), 28% were overweight
(BMI=25–29.9 kg/m2), and 23% were obese (BMI > 30 kg/m2).
There were 3190 controls matched to cases on sex, age, and county of
birth. Type 2 diabetes was recorded in the National Patient Register in 3
(0.9%) cases and 0 controls. The prevalence of lifetime psychiatric
comorbidity in cases and controls is shown in Supplementary Table S3.
Descriptive statistics for annual healthcare utilization and expenditure
are in the Supplement (Table S4). We report means and proportions for
comparability with other research [6,8,9,11].
.
3.2. Health care utilization and costs
We report the pattern of the outcome over the time period. Hurdle
model ORs for utilization (see Fig. 1) and expenditure followed an in-
verted U-shaped curve across time. Eight years before BED diagnosis,
utilization was not significantly different for inpatient
(ORyear−8= 0.78; 0.10, 6.18, FDR p=0.81) or hospital-based out-
patient treatment (ORyear−8= 0.84; 0.33, 2.18, FDR p=0.81). Four
years before BED diagnosis, prescription fills for psychiatric conditions
were higher among cases (ORyear−4= 2.86; 1.65, 4.96, FDR
p < 0.001). The same was true for costs (see Fig. 2). Significant dif-
ferences between cases and controls became apparent in the years be-
fore the index BED diagnosis. Psychiatric care predominantly accounted
for the pre-index differences. ORs for utilization and expenditure
peaked in the index year. For example, cases had significantly higher
odds of inpatient psychiatric care (ORyear 1= 23.06; 9.22, 57.68, FDR
p < 0.001) and of hospital-based outpatient and prescription fill uti-
lization, both overall and for psychiatric conditions. After the index
date, ORs declined annually until there were no significant group dif-
ferences by the end of the observation period. There was an exception
for psychiatric prescription fills; the inverted U-shaped association was
present; however, cases had significantly higher odds of utilization and
expenditure every year observed.
Among those who had at least one occasion of healthcare use, cases
were heavier users than controls of outpatient and medication health-
care in several observed years, and the same for expenditure. An in-
verted U-shaped pattern was evident for the hurdle model IRRs (see the
lower panels in Fig. 1; FDR ps < 0.05). Significant group differences
were observed prior to, during, and in the years after the index date.
The peak differences occurred in the index year for hospital-based
outpatient visits (IRR=3.04, 95% CI=1.98, 4.66, FDR p < 0.001),
prescription medication fills (IRR=2.30, 95% CI=1.84, 2.88, FDR
p < 0.001), hospital-based outpatient expenditure (IRR=1.47, 95%
CI= 1.27, 1.71, FDR p < 0.001), and prescription medication ex-
penditure (IRR=1.96, 95% CI=1.65, 2.34, FDR p < 0.001).
3.3. Supplementary analyses
To evaluate whether utilization for psychiatric conditions was at
least in part attributable to comorbidities, utilization for non-eating
disorder diagnoses only was considered. The same inverted U-shaped
pattern was seen. Cases were significantly more likely to visit outpatient
care over most observed years (FDR ps < 0.05), suggesting that utili-
zation was closely connected with psychiatric comorbidities. The re-
sults are shown fully in Supplementary Table S5.
Utilization for non-BED eating disorders was also considered. Cases
had a significantly higher odds of outpatient psychiatric care for a non-
BED eating disorder from year −4 to 4 (FDR ps < 0.05). Thus at least
part of the group difference was because BED cases had a greater odds
of treatment contact for another eating disorder, and suggests that some
cases experienced a crossover from another eating disorder to BED, or
BED to another eating disorder. Clinically, this is common, given the
similarities between the eating disorders [2]. The full results are shown
in Supplementary Table S6.
3.4. Bootstrap predicted group differences in utilization
The mean differences in annual outpatient visits and prescription
fills (overall and for psychiatric conditions) were statistically significant
in the majority of instances and followed an inverted U-shape over time
(Fig. 3). The peaks occurred near the index date and indicated that
cases had higher inpatient (μyear 1=1.36 days, 95% CI=0.44, 2.41,
p < 0.05), hospital-based outpatient (μyear 1=1.38 visits, 95%
CI= 1.08, 1.73, p < 0.05), and prescription medication utilization
(μyear−1= 4.03 fills, 95% CI= 2.92, 5.18, p < 0.05). The differences
could be attributed to psychiatric conditions for inpatient and hospital-
based outpatient utilization, and for psychiatric and somatic conditions
for prescription medication fills.
3.5. Bootstrap predicted ratio of expenditure
The ratio of the expenditure (cases/controls) rather than the mean
difference was examined, since healthcare costs can vary widely across
countries and a ratio might allow for easier cross-country comparison.
To give a basic idea of cost, the cost of an inpatient day in the sample
was US$1116 (SD=$453), $249 (SD=$67) for an outpatient-based
visit, and $31 (SD=$64) for a prescription fill. Expenditure on care
was significantly greater for cases than controls several years before
and after diagnosis, overall and when restricted to psychiatric illness
only (Fig. 4). At the peaks, for instance, cases had 8 times higher ex-
penditure on inpatient care (μyear−2= 8.28; 2.50, 19.63) and 16 times
higher expenditure on outpatient care for psychiatric reasons (μyear
1= 16.64; 12.18, 23.69, p < 0.05) (μyear 1=2.32; 1.85, 2.90,
p < 0.05). Expected expenditure on annual per-person prescription
fills was significantly elevated for cases between years −1 to 2 for
prescriptions for somatic illness.
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4. Discussion
BED became formalized in DSM-5 [1] and is the most common
eating disorder. Research documenting extensive comorbidity and de-
bilitating effects has proliferated [2,4,7]. Awareness of BED is lacking in
the public and in health care settings and its seriousness remains un-
derappreciated [23]. We show that healthcare burden is observable
years before BED was medically detected, as well as years after. While
controls' healthcare utilization and expenditure remained relatively low
and steady over the observation period, an inverted U-shaped pattern
characterized cases, with a reversal occurring after BED diagnosis. If
replicated, earlier detection and direct intervention for BED may ob-
viate negative health outcomes and associated costs. Our findings ex-
tend previous research limited by shorter observation periods and se-
lected samples [6,8–11].
We hypothesized greater burden for people with BED years before
diagnosis, because there is typically a multiyear delay from clinical
onset to detection of illness [12,13,24] This prediction was supported
and indicates missed opportunities to detect BED. Many primary care
providers are unaware of and have never diagnosed BED [13,25]. Most
individuals with BED have never been asked about problems with binge
eating by a health professional [13]. Unrecognized emotional and
biological consequences of having BED may contribute to greater
healthcare burden. Failure to enter individuals into care that manages
BED symptoms may lead to worse medical outcomes. Binge eating
prospectively predicts metabolic syndrome, poorer mental health, and
impaired functioning, which increase use of psychiatric and somatic
care [2].
Primary care providers and general psychiatrists are well-placed to
improve detection of BED [26]. The data from this study showed some
reversal of healthcare utilization, suggesting that treating BED when
symptoms first emerge may obviate negative health outcomes. Many
patients experience recovery or a reduction in symptoms with treat-
ment [4]. Educating providers and the general population about BED
and reducing stigma may improve recognition and help-seeking [23].
The analyses of utilization and expenditure post-diagnosis were
exploratory. For persons with sleep apnea, healthcare utilization among
cases relative to controls increases as the index year (i.e., diagnosis/
detection) approaches and reverses after the index year (i.e., with
treatment) [27]. In other conditions, such as fibromyalgia and diabetes,
utilization is arrested but is not reversed in the years following treat-
ment [28,29]. In the current study, after diagnosis of BED, the trend of a
progressive increase in healthcare utilization was reversed, and the
difference between cases and controls diminished. Controls showed a
steady amount of utilization over the observed timeframe. Although a
reversal in use of all forms of healthcare was observed among cases,
cases still had significantly higher use of outpatient care and prescrip-
tions for psychiatric illnesses, suggesting healthcare burden years later.
Future research comparing healthcare utilization among acute and re-
covered individuals with BED adjusting for confounds is needed to shed
light on the role of eating disorder recovery in healthcare utilization.
Strengths of this study include an examination of the broadest time
range to date pre- and post-diagnosis, and the use of an unselected
sample of clinically ascertained BED cases from a nationwide registry.
Register data were used, eliminating recall bias in utilization and ex-
penditure. The data source comprised a population of ~2 million in-
dividuals.
Several limitations are apparent. Males comprise a large portion of
those with BED, but were underrepresented [30,31]. We did not have
access to data on some healthcare types (i.e., emergency admission,
Fig. 1. Healthcare Utilization for Binge-Eating Disorder (BED) Cases Compared with Matched Controls for the Years Surrounding the Index Date (Date of BED Diagnosis).
Note. Controls were matched on age, sex, and location of birth. The upper panels of the figure show odds ratio estimates. The vertical reference line indicates the index date and the
horizontal reference line corresponds to a ratio of 1 (i.e., no significant case-control difference if the 95% CI overlaps). For hospital-based outpatient and prescription medication fills
hurdle models captured the ratio of frequency of utilization (i.e., incident rate ratios) among those individuals who had at least one occasion of service. These estimates are shown in the
lower panels. The figures show an inverted U-shaped pattern, such that healthcare utilization in cases begins to escalate years before BED diagnosis, peaks around the year BED is
diagnosed, and begins to decrease thereafter relative to controls.
*False discovery rate (FDR) p < 0.05. **FDR p < 0.01. ***FDR p < 0.001.
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non-hospital based outpatient, over-the-counter medications, medica-
tions given during hospitalization), and some medication categories
(i.e., anti-obesity agents) were not in the data linkage. Cases were
clinically ascertained via specialist clinics and results may not gen-
eralize to less severe patients treated outside specialist services or to
non-treatment seeking individuals [3]. US data suggest that less than
half of those with BED (43.6%) have ever sought treatment [2]. Because
some healthcare such as inpatient treatment has low base rates, it is
harder to detect a difference if it exists. BMI data were unavailable for
controls so it was not possible to adjust for obesity in the analyses. The
National Patient Register does not include eating disorders diagnosed
outside specialist services. Increased contacts with the medical system
and care providers multiplies opportunities for detection of comorbid
illnesses, hence surveillance bias may have contributed to case-control
differences. Although cases and controls were matched on age, sex, and
county of birth, unmeasured confounders could explain the differences
observed.
5. Conclusions and implications
Annual frequency and expenditure on healthcare utilization was
higher than controls for inpatient, outpatient, and prescription medi-
cation healthcare. Because of evidence of under-diagnosis of BED in
primary care [12,13,24,25], elevated resource use before diagnosis of
BED reflects the burden of both comorbidity and BED. A decline in
clinical status was evident years before BED was diagnosed, and utili-
zation and expenditure progressively increased among cases to the year
of BED diagnosis, after which a reversal was apparent. This study calls
on the health system to improve detection of BED and for treatment of
BED symptoms as they emerge. Early treatment may improve health
outcomes and reduce the economic burden of BED.
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Fig. 2. Healthcare Expenditure for Binge-Eating Disorder (BED) Cases Compared with Matched Controls for the Years Surrounding the Index Date (Date of BED Diagnosis).
Note. Controls were matched on age, sex, and location of birth. The upper panels of the figure show odds ratio estimates. The vertical reference line indicates the index date and the
horizontal reference line corresponds to a ratio of 1 (i.e., no significant case-control difference if the 95% CI overlaps). For hospital-based outpatient and prescription medication fills
hurdle models captured the ratio of frequency of utilization (i.e., incident rate ratios) among those individuals who had at least one annual expenditure. These estimates are shown in the
lower panels. The figures show an inverted U-shaped pattern, such that cases' use of healthcare begins to escalate years before BED diagnosis, peaks around the year BED is diagnosed, and
begins to decrease thereafter relative to controls. *False discovery rate (FDR) p < 0.05. **FDR p < 0.01. ***FDR p < 0.001.
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Fig. 3. Bootstrapped Case-to-Control Mean Difference in Utilization Before and After the
Index Date (Date of BED Diagnosis).
Note. Controls were matched on age, sex, and location of birth. The vertical reference line
indicates the index date and the horizontal reference line corresponds to a mean differ-
ence of 0 (i.e., no significant case-control difference if the 95% CI overlaps). Due to sparse
data, some models have missing estimates, near the extremities and estimates for in-
patient overall converged only in years −3 to −1 only. *p < 0.05.
Fig. 4. Bootstrapped Case-to-Control Ratio in Expenditure Before and After the Index
Date (Date of BED Diagnosis).
Note. Controls were matched on age, sex, and location of birth. The vertical reference line
indicates the index date and the horizontal reference line corresponds to a ratio of 1 (i.e.,
no significant case-control difference if the 95% CI overlaps). Due to sparse data, the ratio
of inpatient psychiatry expenditure could not be estimated. *p < 0.05.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jpsychores.2018.02.011.
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